肝病是心血管结局的重要危险因素——一项英国生物银行研究
该研究基于英国生物银行影像子研究,对33,616名参与者用铁校正T1映射(cT1)评估肝病活动度,采用多因素Cox回归分析其与主要心血管事件、心血管住院和全因死亡的关系。中位随访2.5年,cT1与主要心血管事件、房颤、心衰、心血管住院和全因死亡风险升高独立相关,且在无代谢综合征者中亦然。
要点
- 肝病活动度(cT1)与主要心血管事件风险升高相关(HR 1.14)。
- cT1与房颤(HR 1.30)、心衰(HR 1.30)、心血管住院(HR 1.27)和全因死亡(HR 1.19)风险升高相关。
- 在无代谢综合征者中,cT1仍与心血管住院风险独立相关(HR 1.26)。
核心结论
- 肝病活动度(以cT1衡量)与初发心血管疾病和全因死亡风险升高独立相关,且独立于既存代谢综合征、肝纤维化或肝脏脂肪。
研究设计与样本
- 基于英国生物银行影像子研究,于2016年1月至2020年2月使用LiverMultiScan®测量肝病活动度(cT1)和肝脏脂肪(质子密度脂肪分数[PDFF]),采用多因素Cox回归分析关联。
- 共纳入33,616名具有完整MRI肝脏数据并链接临床结局的参与者,平均年龄65岁,平均BMI 26 kg/m2,平均血红蛋白A1c 35 mmol/mol。
- 主要心血管事件发病中位时间1.4年(范围0.002-5.1),随访2.5年(范围1.1-5.2)。
主要发现
- 肝病活动度(cT1)而非肝脏脂肪(PDFF)与任何主要心血管事件风险升高相关(HR 1.14;95%CI 1.03-1.26;p=0.008)。
- cT1与房颤(HR 1.30;95%CI 1.12-1.51;p<0.001)、心衰(HR 1.30;95%CI 1.09-1.56;p=0.004)、心血管住院(HR 1.27;95%CI 1.18-1.37;p<0.001)和全因死亡(HR 1.19;95%CI 1.02-1.38;p=0.026)风险升高相关。
- FIB-4指数与心衰相关(HR 1.06;95%CI 1.01-1.10;p=0.007)。
- 在无代谢综合征的个体中,心血管住院风险与cT1独立相关(HR 1.26;95%CI 1.13-1.4;p<0.001)。
临床怎么用
- 作者认为,这些发现强调在心血管疾病和/或慢性肝病风险人群中全面评估肝脏健康的预后相关性,即使在无临床表现或代谢综合征时亦然,此时有机会调整/处理危险因素并预防疾病进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic liver disease (CLD) is associated with increased cardiovascular disease (CVD) risk. We investigated whether early signs of liver disease (measured by iron-corrected T1-mapping [cT1]) were associated with an increased risk of major CVD events. METHODS: Liver disease activity (cT1) and fat (proton density fat fraction [PDFF]) were measured using LiverMultiScan® between January 2016 and February 2020 in the UK Biobank imaging sub-study. Using multivariable Cox regression, we explored associations between liver cT1 (MRI) and primary CVD (coronary artery disease, atrial fibrillation [AF], embolism/vascular events, heart failure [HF] and stroke), and CVD hospitalisation and all-cause mortality. Liver blood biomarkers, general metabolism biomarkers, and demographics were also included. Subgroup analysis was conducted in those without metabolic syndrome (defined as at least three of: a large waist, high triglycerides, low high-density lipoprotein cholesterol, increased systolic blood pressure, or elevated haemoglobin A1c). RESULTS: A total of 33,616 participants (mean age 65 years, mean BMI 26 kg/m2, mean haemoglobin A1c 35 mmol/mol) had complete MRI liver data with linked clinical outcomes (median time to major CVD event onset: 1.4 years [range: 0.002-5.1]; follow-up: 2.5 years [range: 1.1-5.2]). Liver disease activity (cT1), but not liver fat (PDFF), was associated with higher risk of any major CVD event (hazard ratio 1.14; 95% CI 1.03-1.26; p = 0.008), AF (1.30; 1.12-1.51; p <0.001); HF (1.30; 1.09-1.56; p= 0.004); CVD hospitalisation (1.27; 1.18-1.37; p <0.001) and all-cause mortality (1.19; 1.02-1.38; p = 0.026). FIB-4 index was associated with HF (1.06; 1.01-1.10; p = 0.007). Risk of CVD hospitalisation was independently associated with cT1 in individuals without metabolic syndrome (1.26; 1.13-1.4; p <0.001). CONCLUSION: Liver disease activity, by cT1, was independently associated with a higher risk of incident CVD and all-cause mortality, independent of pre-existing metabolic syndrome, liver fibrosis or fat. IMPACT AND IMPLICATIONS: Chronic liver disease (CLD) is associated with a twofold greater incidence of cardiovascular disease. Our work shows that early liver disease on iron-corrected T1 mapping was associated with a higher risk of major cardiovascular disease (14%), cardiovascular disease hospitalisation (27%) and all-cause mortality (19%). These findings highlight the prognostic relevance of a comprehensive evaluation of liver health in populations at risk of CVD and/or CLD, even in the absence of clinical manifestations or metabolic syndrome, when there is an opportunity to modify/address risk factors and prevent disease progression. As such, they are relevant to patients, carers, clinicians, and policymakers.
引用
- Roca-Fernandez A, Banerjee R, Thomaides-Brears H, et al. Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study. J Hepatol. 2023. PMID: 37348789. doi:10.1016/j.jhep.2023.05.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。